ADBiotech Co., Ltd. (KOSDAQ:179530)
South Korea · Delayed Price · Currency is KRW 3,225.00
-65.00 (-1.98%)
At close: Sep 16, 2025
ADBiotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 12,673 | 11,136 | 10,472 | 10,632 | 11,840 | 9,815 |
Other Revenue | 0 | - | -0 | -0 | -0 | - |
| 12,673 | 11,136 | 10,472 | 10,632 | 11,840 | 9,815 | |
Revenue Growth (YoY) | 29.00% | 6.34% | -1.50% | -10.21% | 20.63% | - |
Cost of Revenue | 7,619 | 7,130 | 7,254 | 7,520 | 6,831 | 5,416 |
Gross Profit | 5,054 | 4,007 | 3,218 | 3,111 | 5,009 | 4,400 |
Selling, General & Admin | 5,939 | 5,833 | 6,239 | 6,284 | 5,333 | 4,369 |
Research & Development | 1,799 | 1,632 | 1,486 | 1,111 | 550.16 | 788.46 |
Other Operating Expenses | 125.6 | 142.67 | 147.27 | 126.59 | 119.71 | 68.94 |
Operating Expenses | 8,983 | 8,124 | 7,990 | 8,095 | 6,564 | 5,396 |
Operating Income | -3,929 | -4,117 | -4,772 | -4,984 | -1,555 | -996.2 |
Interest Expense | -862.04 | -682.06 | -426.4 | -124.68 | -130.23 | -579.54 |
Interest & Investment Income | 34.23 | 76.48 | 149.67 | 6,019 | 5.73 | 9.55 |
Currency Exchange Gain (Loss) | -56.74 | 150.94 | -38.62 | -39.66 | 64.42 | -42.65 |
Other Non Operating Income (Expenses) | -727.55 | 248.95 | -813.25 | 1,435 | -777.68 | -5,992 |
EBT Excluding Unusual Items | -5,541 | -4,323 | -5,901 | 2,306 | -2,392 | -7,601 |
Gain (Loss) on Sale of Investments | -365.95 | -4,263 | 3,023 | 390.47 | -24.16 | 75.36 |
Gain (Loss) on Sale of Assets | -1.75 | -4.43 | - | - | 1.82 | 2.27 |
Asset Writedown | -1,925 | -421.96 | -2,580 | - | - | - |
Pretax Income | -7,834 | -9,013 | -5,457 | 2,696 | -2,415 | -7,476 |
Income Tax Expense | -192.54 | -25.72 | -25.58 | - | 249.77 | -131.32 |
Earnings From Continuing Operations | -7,642 | -8,987 | -5,432 | 2,696 | -2,664 | -7,345 |
Minority Interest in Earnings | 351.09 | 1,035 | 2,568 | - | - | - |
Net Income | -7,290 | -7,952 | -2,863 | 2,696 | -2,664 | -7,345 |
Net Income to Common | -7,290 | -7,952 | -2,863 | 2,696 | -2,664 | -7,345 |
Shares Outstanding (Basic) | 10 | 9 | 9 | 9 | 8 | 5 |
Shares Outstanding (Diluted) | 10 | 9 | 9 | 10 | 8 | 5 |
Shares Change (YoY) | 7.67% | - | -9.33% | 31.17% | 53.77% | - |
EPS (Basic) | -740.81 | -869.98 | -313.27 | 297.39 | -346.68 | -1469.52 |
EPS (Diluted) | -740.81 | -870.00 | -313.27 | 118.54 | -347.00 | -1470.00 |
Free Cash Flow | -4,563 | -4,285 | 75.03 | -9,319 | -5,747 | -6,308 |
Free Cash Flow Per Share | -463.71 | -468.81 | 8.21 | -924.41 | -747.71 | -1262.15 |
Gross Margin | 39.88% | 35.98% | 30.73% | 29.26% | 42.31% | 44.82% |
Operating Margin | -31.01% | -36.97% | -45.57% | -46.88% | -13.13% | -10.15% |
Profit Margin | -57.53% | -71.41% | -27.34% | 25.36% | -22.50% | -74.83% |
Free Cash Flow Margin | -36.01% | -38.48% | 0.72% | -87.66% | -48.54% | -64.27% |
EBITDA | -2,915 | -3,092 | -3,639 | -4,258 | -903 | -815.11 |
EBITDA Margin | -23.00% | -27.77% | -34.75% | -40.05% | -7.63% | -8.30% |
D&A For EBITDA | 1,014 | 1,025 | 1,134 | 725.66 | 651.6 | 181.09 |
EBIT | -3,929 | -4,117 | -4,772 | -4,984 | -1,555 | -996.2 |
EBIT Margin | -31.01% | -36.97% | -45.57% | -46.88% | -13.13% | -10.15% |
Advertising Expenses | - | 76.26 | 1.06 | 344.51 | 271.87 | 8.37 |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.